[Image courtesy of Walmart]
After a banner year for diabetes technology in 2022, there’s still plenty to look forward to in 2023.
Throughout 2022, we saw a wide range of advancements in diabetes technology. We saw launches for next-generation technologies, exciting clinical trial results, rumored spinouts and acquisitions and more.
You can read all about the biggest diabetes stories of 2022 here.
As we embark on a new year in 2023, there’s still plenty to look forward to in the diabetes space. Here are a few things worth keeping an eye on.
CMS decision could benefit CGMs
In October, The Centers for Medicare and Medicaid Services (CMS) published a new local coverage determination (LCD). That LCD modified coverage criteria for continuous glucose monitors (CGMs). The modification includes people with diabetes who receive insulin treatment or have a history of problematic hypoglycemia.
Analysts suggested at the time that the decision marked a win for CGM makers, including Abbott and Dexcom.
